Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,696 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Autologous hematopoietic stem cell transplantation Clear all
Completed Phase 1 Interventional

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

NCT04155710
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
IOV-2001, Low dose IL-2, High dose IL-2, IL-2
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Durham, North Carolina • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 2 Interventional

Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma

NCT00002221
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Peripheral blood stem cells
Drug
Lead sponsor
Ribozyome
Industry
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer

NCT00005816
View directory record Official record
Conditions
Kidney Cancer
Interventions
therapeutic autologous dendritic cells, conventional surgery
Biological · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Not applicable Interventional Results available

Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use

NCT01648491
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Muscle Biopsy, Injection of autologous stem cells
Procedure · Biological
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
78 Years to 82 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View directory record Official record
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 22, 2026, 11:05 PM EDT
Terminated Not applicable Interventional

Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

NCT05809245
View directory record Official record
Conditions
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
Interventions
Corneal neurotization
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 22, 2026, 11:05 PM EDT
Not listed Phase 2 Interventional

Ovarian Dendritic Cell Vaccine Trial

NCT00703105
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DC vaccination
Biological
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL

NCT00477945
View directory record Official record
Conditions
Non Hodgkin's Lymphoma
Interventions
clofarabine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 22, 2026, 11:05 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

NCT05312801
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Interventions
BAFF CAR-T
Drug
Lead sponsor
Luminary Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 22, 2026, 11:05 PM EDT
Terminated Phase 1 Interventional

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease

NCT00058773
View directory record Official record
Conditions
Hodgkin Disease, Non-Hodgkins Lymphoma
Interventions
Infusion of EBV Specific Cytotoxic T-Lymphocytes
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 22, 2026, 11:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT03277729
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis, Leukapheresis, Fludarabine Phosphate
Biological · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2039
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 11:05 PM EDT
Terminated Phase 2 Interventional Results available

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

NCT03622775
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Daratumumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 22, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

KRDI in Transplant-Eligible MM

NCT04430894
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

NCT00923351
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar, Neuroectodermal Tumors, Primitive, Peripheral
Interventions
Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7, Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Months to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Early Phase 1 Interventional

A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients

NCT03284242
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplant
Interventions
Treg
Drug
Lead sponsor
Roberto Gedaly
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 22, 2026, 11:05 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

NCT04228666
View directory record Official record
Conditions
Alzheimer Disease
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 22, 2026, 11:05 PM EDT
Recruiting Phase 1 Interventional

The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis

NCT04929951
View directory record Official record
Conditions
Osteoarthritis Shoulder, Shoulder Pain
Interventions
Micro Fragmented Adipose Tissue, Corticosteroid injection
Biological
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

NCT01896102
View directory record Official record
Conditions
Cerebral Adrenoleukodystrophy (CALD)
Interventions
Lenti-D Drug Product (eli-cel)
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 2 Interventional

Efficacy of Injection Therapy for Lateral Epicondylosis

NCT01476605
View directory record Official record
Conditions
Tennis Elbow
Interventions
Dextrose prolotherapy, PrT-DMS, Platelet Rich Plasma injection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 22, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

NCT04146051
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Descartes-08
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Carlsbad, California • Irvine, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease

NCT00316121
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
HEALOS and Leopard Cage, Leopard Cage and Autograft
Device
Lead sponsor
Advanced Technologies and Regenerative Medicine, LLC (ATRM)
Other
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
17
States / cities
Little Rock, Arkansas • Beverly Hills, California • Brandon, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 1 Interventional

Autologous Vaccine for Follicular Lymphoma

NCT01022255
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Autologous FL vaccine
Biological
Lead sponsor
Icon Genetics GmbH
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Burbank, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 22, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Results available

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

NCT03019055
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 22, 2026, 11:05 PM EDT
Active, not recruiting Phase 1 Interventional

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05973487
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
Biological
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 22, 2026, 11:05 PM EDT